Drug intelligence / Profile preview

PRT-042

Development stage: Phase 2
Lead developer: Sichuan Prite Pharmaceutical
Modality: Small Molecules
Administration: Intranasal

Overview

PRT-042 is an intranasal formulation of (R)-ketamine hydrochloride (arketamine) developed by Sichuan Purity Pharmaceutical Technology. It is currently in Phase 2 clinical development for the treatment of major depressive disorder (MDD) in patients with acute suicidal ideation or behavior. As the R-enantiomer of ketamine, it functions as a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist. PRT-042 aims to provide rapid-acting antidepressant effects by modulating the glutamate neurotransmitter system, potentially offering a different safety and efficacy profile compared to the approved S-enantiomer, esketamine.

Other names: (R)-ketamine hydrochloridearketamine hydrochlorideR-ketamine hydrochloride

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)

Beyond the preview

Go deeper on PRT-042.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PRT-042.

Explore the full profile